DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation

Information source: Stanford University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Fetal Distress

Intervention: Terbutaline (Drug)

Phase: N/A

Status: Completed

Sponsored by: Stanford University

Official(s) and/or principal investigator(s):
Yasser Yehia El-Sayed, Principal Investigator, Affiliation: Stanford University


To compare nitroglycerin and terbutaline for intrapartum fetal heart rate resuscitation

Clinical Details

Official title: Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: resolution of abnormal fetal heart tracing

Secondary outcome:

cesarean section rate

operative vaginal delivery rate

neonatal outcomes


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria::

- nonreassuring fetal heart rate tracing

Exclusion Criteria:- maternal cardiac disease, placental abruption, intrauterine growth restriction, prior cesarean section

Locations and Contacts

Stanford University School of Medicine, Stanford, California 94305, United States
Additional Information

American Journal of Obstetrics and Gynecology. 2007 Oct;197(4):414.el-6

Starting date: October 2003
Last updated: March 4, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017